The mission of St. Jude Children's Research Hospital is to find cures for children with catastrophic illnesses through research and treatment. The resources of the hospital have been focused on pediatric cancer throughout its 44 year history and the Cancer Center has been supported by a CCSG for 29 years. Through the support of the American Lebanese Syrian Associated Charities (ALSAC), a separate corporation whose only purpose is to raise money in support of St. Jude Children's Research Hospital, patients are accepted without regard to ability to pay. Public support of the hospital through ALSAC provides a strong foundation for our Cancer Center upon which extramurally funded research and CCSG support can be leveraged to their fullest potential. In the current application, six multidisciplinary research programs are described. The Molecular Oncology (MO) and Signal Transduction (ST) Programs focus on basic, discovery-oriented research. The Developmental Therapeutics for Solid Malignancies (DTSM), Hematologic Malignancies (HM), Neurobiology and Brain Tumor (NBT), and Cancer Prevention and Control (CPC) Programs emphasize the translation of laboratory or population science to clinical application. The latter program is new to this application and represents the culmination of a long-standing commitment to long-term follow-up of our patient population, a recent commitment to population sciences, and successful recruitment of a world-class scientist to lead efforts in this area. Research by the 139 members of the Cancer Center is supported by 12 Shared Resources and an outstanding clinical research infrastructure. During the previous funding period, a new Cancer Center Director was appointed and the overall structure of our Cancer Center and its leadership were enhanced by several organizational changes, including bringing the infrastructure supporting the expansive clinical trials efforts administratively under the Cancer Center's authority. Several Program leader changes and the successful recruitment of three new outstanding Department Chairs (Immunology, Chemical Biology, and Epidemiology/Cancer Control) during the last funding period significantly enhance the multidisciplinary science done by our Cancer Center Programs. St. Jude Cancer Center investigators had over 2000 cancer-related publications during the funding period, 20% of which represented intraprogrammatic interactions and 15% of which were inter-programmatic. Extramural support for cancer research done at St. Jude is currently over $50 million per year, $31 million of which is from the NCI/HHMI. St. Jude Children's Research Hospital recently went through a vigorous Strategic Planning process and made a strong and long-term commitment to remain focused on cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA021765-34S4
Application #
8637118
Study Section
Special Emphasis Panel (ZCA1-RTRB-Z (O1))
Program Officer
Marino, Michael A
Project Start
1997-04-01
Project End
2014-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
34
Fiscal Year
2013
Total Cost
$5,527,034
Indirect Cost
$2,368,729
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Levine, Jennifer M; Whitton, John A; Ginsberg, Jill P et al. (2018) Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 124:1044-1052
Li, Jian-Feng; Dai, Yu-Ting; Lilljebjörn, Henrik et al. (2018) Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci U S A 115:E11711-E11720
Scott, Jessica M; Li, Nan; Liu, Qi et al. (2018) Association of Exercise With Mortality in Adult Survivors of Childhood Cancer. JAMA Oncol 4:1352-1358
Rong, Yongqi; Bansal, Parmil K; Wei, Peng et al. (2018) Glycosylation of Cblns attenuates their receptor binding. Brain Res 1694:129-139
Zheng, Wenting; O'Hear, Carol E; Alli, Rajshekhar et al. (2018) PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia 32:1157-1167
Heikamp, Emily B; Pui, Ching-Hon (2018) Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia. J Pediatr 203:14-24.e2
Sharma, Akshay; Kang, Guolian; Sunkara, Anusha et al. (2018) Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms. J Pediatr Hematol Oncol 40:e479-e485
Waszak, Sebastian M; Northcott, Paul A; Buchhalter, Ivo et al. (2018) Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 19:785-798
Penkert, Rhiannon R; Hurwitz, Julia L; Thomas, Paul et al. (2018) Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia. Haematologica 103:e50-e54
Turner, Benjamin L; Brenes-Arguedas, Tania; Condit, Richard (2018) Pervasive phosphorus limitation of tree species but not communities in tropical forests. Nature 555:367-370

Showing the most recent 10 out of 6764 publications